SCULLY WILLIAM P purchased $1.8M of PRTA (indirect holdings)
SCULLY WILLIAM P purchased 215,000 indirectly-held shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at an average of $8.47 ($8.40–$8.57, $1.82M total) across 2 trades over 2026-10-07 to 2026-10-08.
How this was made
The 30-second read
Why it matters
The insider purchase adds credibility to the company's pipeline but is unlikely to trigger a significant price move given the company's low float and the modest transaction size.
Market read
Primary insider transaction; modest relevance for short‑term traders monitoring PRTA.
What to watch
The insider's total holding remains a small percentage of float; market may discount the buy.
Background
Prothena Corp Public Ltd (PRTA) is a clinical‑stage biotech focused on rare diseases. The filing reports a 10% owner increasing his stake via open‑market purchases.
Ticker impact
SEC Form 4 shows insider William Scully purchased $1.8M of PRTA shares, increasing his stake to 529,000 shares.
likely slight upward pressure as the market prices in the insider purchase
The purchase is sizable for a micro‑cap but not large enough to move the price dramatically; investors often view insider buys as a bullish signal.
Market effects
Minimal impact on the broader biotech sector; the filing is company‑specific.
None
None
Counterpoint
The purchase could be a routine portfolio rebalancing rather than a strong confidence signal.
Key entities
- InsiderWilliam Scully
10% owner of PRTA who executed the purchase.
